ridaforolimus + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Soft-Tissue Sarcomas
Conditions
Metastatic Soft-Tissue Sarcomas, Metastatic Bone Sarcomas
Trial Timeline
Oct 1, 2007 → Dec 1, 2012
NCT ID
NCT00538239About ridaforolimus + Placebo
ridaforolimus + Placebo is a phase 3 stage product being developed by Merck for Metastatic Soft-Tissue Sarcomas. The current trial status is completed. This product is registered under clinical trial identifier NCT00538239. Target conditions include Metastatic Soft-Tissue Sarcomas, Metastatic Bone Sarcomas.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Soft-Tissue Sarcomas were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00538239 | Phase 3 | Completed |
Competing Products
20 competing products in Metastatic Soft-Tissue Sarcomas